Acne Vulgaris Pipeline Therapeutics Assessment Report 2024 (Updated)

DelveInsight's, "Acne Vulgaris Pipeline Insight 2024" report provides comprehensive insights about 20+ companies and 22+ pipeline drugs in Acne Vulgaris pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Explore our latest breakthroughs in Acne Vulgaris Research. Learn more about our innovative pipeline today! @ Acne Vulgaris Pipeline Outlook- https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Key Takeaways from the Acne Vulgaris Pipeline Report
• In November 2024:- Ascletis Pharmaceuticals-This is a multicenter, open-label study designed to determine the long-term safety of ASC40 (Denifanstat) tablets in patients with moderate to severe acne vulgaris enrolled in the ASC40-303 Phase III study. All subjects are eligible for study eligibility screening after enrollment in ASC40-303 Phase III study, and all eligible subjects with moderate to severe acne vulgaris will receive ASC40 (Denifanstat) tablets after signing informed consent. The investigational drug will be administered orally once daily (QD) for up to 40 weeks. There will be a total of 7 visits for screening and follow-up. The tests required by the program included routine blood tests, blood biochemistry, lipid profile, pregnancy test and urine routine, etc.
• In November 2024:- UCB Biopharma SRL- A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating the Long-Term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa. The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
• DelveInsight's Acne Vulgaris pipeline report depicts a robust space with 20+ active players working to develop 22+ pipeline therapies for Acne Vulgaris treatment.
• The leading Acne Vulgaris Companies such as Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals, and others.
• Promising Acne Vulgaris Therapies such as Clascoterone, DMT310, Winlevi (clascoterone) 1% cream, Erythromycin 4% topical gel formulation, and others.

Stay informed about the cutting-edge advancements in Acne Vulgaris treatments. Download for updates and be a part of the revolution in care @ Acne Vulgaris Clinical Trials Assessment- https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acne Vulgaris Emerging Drugs Profile
• Berdazimer sodium (SB 204) : Pelthos Therapeutics
SB204 is a first-in-class nitric oxide (NO)-releasing topical treatment monotherapy. The Phase 2b study demonstrated statistically significant reductions in the percent change of non-inflammatory (white heads and black heads) and inflammatory (larger red bumps and pustules) lesions at Week 12 with all doses of SB204 compared to vehicle. SB204 demonstrated excellent cutaneous tolerability with no treatment-related serious adverse events in over 400 dosed subjects to date. Currently, the drug is in Phase III stage of its development for the treatment of acne vulgaris.
• DMT310: Dermata Therapeutics
DMT310 is a lead product candidate, developed from our Spongilla platform technology. The unique product candidate is derived from a natural source of Spongilla lacustris, which contains multiple active components to treat a variety of inflammatory skin diseases with once weekly applications. It is currently under development for the treatment of moderate to severe acne, mild to moderate psoriasis and moderate to severe papulopustular rosacea. It contains a unique freshwater sponge that is harvested from a select region of the world, under specific environmental conditions to ensure the sponge retains its distinctive anti-inflammatory, anti-microbial and mechanical properties. Currently, the drug is in Phase III stage of its development for the treatment of acne vulgaris.
• GT 20029 : Suzhou Kintor Pharmaceuticals
GT-20029 is a small molecule that works on Androgen receptor degradation enhancer's mechanism of action. It is administered through topical route as gel/tincture form. The drug candidate acts by targeting androgen receptor and cereblon (CRBN). It is being developed based on PROTAC (Protein Degradation Targeting Chimera) technology. Currently, the drug is in Phase I stage of its development for the treatment of acne vulgaris.

Learn more about Acne Vulgaris Drugs opportunities in our groundbreaking Acne Vulgaris Research and development projects @ Acne Vulgaris Unmet Needs- https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Acne Vulgaris Companies
Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals, and others.

Acne Vulgaris pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Acne Vulgaris Products have been categorized under various Molecule types such as
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Discover the latest advancements in Acne Vulgaris treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Acne Vulgaris Market Drivers and Barriers, and Future Perspectives- https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Acne Vulgaris Pipeline Report
• Coverage- Global
• Acne Vulgaris Companies- Pelthos Therapeutics, Dermata Therapeutics, Suzhou Kintor Pharmaceuticals, Naked Biome, Inc, AOBiome LLC, Dermira, Inc., Sol-Gel Technologies, Ltd., Torrent Pharmaceuticals Limited, Galderma R&D, Boston Pharmaceuticals, and others.
• Acne Vulgaris Therapies- Clascoterone, DMT310, Winlevi (clascoterone) 1% cream, Erythromycin 4% topical gel formulation, and others.
• Acne Vulgaris Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Acne Vulgaris Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

For a detailed overview of our latest research findings and future plans, read the full details of Acne Vulgaris Pipeline on our website @ Acne Vulgaris Emerging Drugs and Companies- https://www.delveinsight.com/sample-request/acne-vulgaris-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Introduction
2. Executive Summary
3. Acne vulgaris: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Late Stage Products (Phase III)
7. Berdazimer sodium (SB 204) : Pelthos Therapeutics
8. Drug profiles in the detailed report…..
9. Mid Stage Products (Phase II)
10. Drug Name: Company Name
11. Drug profiles in the detailed report…..
12. Early Stage Products (Phase I)
13. GT 20029 : Suzhou Kintor Pharmaceuticals
14. Drug profiles in the detailed report…..
15. Inactive Products
16. Acne vulgaris Key Companies
17. Acne vulgaris Key Products
18. Acne vulgaris- Unmet Needs
19. Acne vulgaris- Market Drivers and Barriers
20. Acne vulgaris- Future Perspectives and Conclusion
21. Acne vulgaris Analyst Views
22. Acne vulgaris Key Companies
23. Appendix

List of Top Selling Market Research Reports in 2024

carcinoid syndrome market- https://www.delveinsight.com/report-store/carcinoid-tumor-market
fabry disease market- https://www.delveinsight.com/report-store/fabry-disease-market
gene therapy in cns disorder market- https://www.delveinsight.com/report-store/gene-therapy-in-cns-disorder-market
lice infestations market- https://www.delveinsight.com/report-store/lice-infestations-market
surgical lasers market- https://www.delveinsight.com/report-store/surgical-lasers-market
transcatheter treatment market - https://www.delveinsight.com/report-store/transcatheter-aortic-valve-replacement-market
wound healing devices market- https://www.delveinsight.com/report-store/wound-healing-devices-market
intraocular lens market- https://www.delveinsight.com/blog/top-companies-in-the-intraocular-lens-market
scoliosis market - https://www.delveinsight.com/report-store/scoliosis-market
stem cell market- https://www.delveinsight.com/report-store/stem-cell-market
surgical mask & respirator market- https://www.delveinsight.com/report-store/surgical-mask-respirator-market
urea cycle disorders market- https://www.delveinsight.com/blog/urea-cycle-disorder-market
vitreoretinal surgery devices market- https://www.delveinsight.com/report-store/vitreoretinal-surgery-devices-market
diabetic wound market- https://www.delveinsight.com/report-store/diabetic-foot-ulcers-dfus-market
lymphoedema market- https://www.delveinsight.com/report-store/lymphedema-market
nk cell therapy market- https://www.delveinsight.com/report-store/nk-cell-therapy-market
pacemakers market- https://www.delveinsight.com/report-store/pacemakers-market
sglt2 inhibitors market- https://www.delveinsight.com/report-store/sglt2-inhibitors-market
urinary catheters market- https://www.delveinsight.com/report-store/urinary-catheters-market
cardiac monitoring devices market- https://www.delveinsight.com/report-store/cardiac-monitoring-devices-market
indwelling catheters market- https://www.delveinsight.com/report-store/indwelling-catheters-market
mouth neoplasms market- https://www.delveinsight.com/sample-request/mouth-neoplasms-market
somatotropin deficiency market - https://www.delveinsight.com/report-store/somatotropin-deficiency-market
meningococcal meningitis market- https://www.delveinsight.com/report-store/meningococcal-meningitis-market
seltorexant drug market- https://www.delveinsight.com/report-store/major-depressive-disorder-market
surgical energy instruments market- https://www.delveinsight.com/report-store/surgical-energy-instruments-electrosurgical-devices-market
varicose vein treatment devices market- https://www.delveinsight.com/report-store/varicose-vein-treatment-devices-market
healthcare competitive benchmarking- https://www.delveinsight.com/consulting/competitive-benchmarking-services
bone growth stimulator market- https://www.delveinsight.com/report-store/bone-growth-stimulators-market
antibody drug conjugate market - https://www.delveinsight.com/report-store/antibody-drug-conjugate-market
microscopy device market- https://www.delveinsight.com/report-store/microscopy-device-market
novel drug delivery devices market- https://www.delveinsight.com/report-store/novel-drug-delivery-devices
total knee arthroplasty market- https://www.delveinsight.com/report-store/total-knee-arthroplasty-market
skin neoplasm market- https://www.delveinsight.com/report-store/basal-cell-carcinoma-basal-cell-epithelioma-market
asperger syndrome market- https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market
pipeline assessment services- https://www.delveinsight.com/consulting/pipeline-assessment-services
lactose intolerance market- https://www.delveinsight.com/report-store/lactose-intolerance-market

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

This release was published on openPR.